BofA raises Abbvie stock price target on Apogee deal close

BofA raised AbbVie’s price target to $282 from $276 and maintained Buy after the Apogee acquisition closed, modeling $7.5B in nominal and $5B risk-adjusted peak sales for zumilokibart in atopic dermatitis. AbbVie has funded the Apogee deal with an $8.0B senior-notes offering and reported Q2 2026 revenue of $16.99B and adjusted EPS of $3.65, above Guggenheim estimates. Additional bullish targets include $288 from Guggenheim and $300 from Wells Fargo, although ABBV at $256.46 is near its $267.47 52-week high and is viewed as overvalued by InvestingPro.

Analysis

ABBV’s incremental immunology upside is strategically more valuable than the headline peak-sales estimate implies because it extends the company’s ability to bundle dermatology prescriber relationships across Skyrizi, Rinvoq and a future long-interval biologic. The commercial hurdle is high: REGN/SNY’s Dupixent remains entrenched, while LLY’s Ebglyss expands the IL-13 competitive set. A genuinely durable every-12/24-week profile could reduce administration burden and support premium persistence, but the value is concentrated in Phase 3 differentiation rather than in near-term earnings.

The market is likely underwriting pipeline de-risking before clinical proof while giving limited weight to acquisition-financing costs. The $8B debt raise is manageable against ABBV cash generation, but it raises the sensitivity of equity upside to rates, integration execution, and whether acquired assets displace internal R&D rather than add incremental revenue. Over the next 1-3 months, ABBV can continue to rerate with immunology and neuroscience estimate revisions; over 6-18 months, the key risk is that the market applies a lower probability of success if dosing durability, safety, or efficacy versus standard biologics is not clearly differentiated.

Contrarian view: the sell-side target increases appear driven partly by multiple expansion rather than materially changed near-term cash flow. At an elevated valuation, ABBV needs continued beats from its marketed portfolio to justify paying today for revenue that is still several years from launch. The cleaner relative expression is not outright short ABBV, but long ABBV versus a large-cap pharma peer with weaker post-LOE visibility, while retaining explicit clinical-event risk controls.

Key Decisions for Investors

• Initiate a modest long ABBV / short PFE pair over a 3-6 month horizon. ABBV has superior medium-term immunology visibility, while PFE remains more exposed to post-COVID revenue reset and pipeline execution; target 8-12% relative return. Exit if ABBV immunology guidance is reduced or the relative spread underperforms by 7%.
• Do not chase APGE without the cash/stock consideration, closing conditions, and expected deal-close date. If APGE trades at a material discount to disclosed consideration after reviewing antitrust and financing terms, treat it as a merger-arbitrage watch item rather than a standalone biotech long.
• For existing ABBV longs, use a 6-9 month collar rather than adding unhedged exposure near highs: sell upside calls near the analyst-target range and buy puts 8-10% below spot. This preserves participation in estimate revisions while limiting downside from a Phase 3 differentiation failure or a broad pharma multiple derating.
• Monitor REGN, SNY and LLY dermatology commentary during upcoming earnings for evidence of payer pushback, persistence trends, and biologic switching. Strong Ebglyss uptake or sustained Dupixent share gains would lower the probability that ABBV’s future asset achieves premium peak-sales assumptions; reduce ABBV exposure if management’s implied market-share thesis is contradicted.